Refine by
Carcinoma Technology
16 companies found
Technologybased inMountain View, CALIFORNIA (USA)
Osel’s mission is to develop and commercialize a broad portfolio of Live Biotherapeutic Products (LBPs) that prevent or treat abnormal conditions resulting from a disruption of the human microbiome. In 2003, Osel was one of the first companies to ...
CBM588 is an orally-administered Clostridium butyricum strain with a long history of clinical use and safety in all age groups in Japan. In Japan, CBM588 has primarily been used to treat infectious and noninfectious diarrheal disorders associated ...
Technologybased inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
MT-303 represents the first candidate in a new therapeutic modality targeting hepatocellular carcinoma (HCC). Liver cancer is a prevalent and challenging cancer with over 850,000 new cases diagnosed globally each year, and the third ...
Technologybased inNewtown, PENNSYLVANIA (USA)
Formely known as Onconova Therapeutics, Inc. Traws Pharma is a clinical stage biopharmaceutical company developing small molecule oral product candidates for respiratory viral diseases and cancer. In the viral respiratory disease space, Traws Pharma ...
Rigosertib is a small molecule that inhibits multiple cellular signaling pathways driving cancer cell growth while having little effect on normal cells. In contrast to many kinase inhibitors, rigosertib does not interact at the ATP binding site, but ...
Technologybased inWoburn, MASSACHUSETTS (USA)
Founded in 2007, HUABIO is dedicated to developing curated, high-quality antibodies that advance innovation. We're passionate about the accuracy, efficiency, and consistency of our products. We devote our company mission to the disruption of an ...
ICC staining of PRMT1 in D3 cells (red). Formalin fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 10 minutes at room temperature and blocked with 1% Blocker BSA for 15 minutes at room temperature. Cells were probed with the primary ...
Technologybased inVienna, AUSTRIA
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...
Technologybased inNangang Distric, TAIWAN
We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ...
TLC178 is our proprietary NanoX™ formulation of the anticancer drug vinorelbine, developed for the treatment of rhabdomyosarcoma (RMS), a rare form of soft tissue sarcoma that most frequently occurs in ...
Technologybased inMerion, PENNSYLVANIA (USA)
Glycotest is a liver disease diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis. Founded in 2012 by NetScientific plc on technology originating at the Baruch S. Blumberg ...
Glycotest blood tests are being developed to provide information on the likelihood of serious liver disease like cancer or fibrosis-cirrhosis by employing technology designed to measure two kinds of disease signals: The amount of the monosaccharide ...
Technologybased inBengaluru, INDIA
At OncoStem, we develop innovative prognostic tests that assess aggressiveness of tumours based on in-depth knowledge of tumour biology, to identify the unique characteristics of cancer recurrence risk. Since 2011, our vision is to empower the ...
Technologybased inFriendswood, TEXAS (USA)
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and ...
Predicting Individual Risk of Metastasis: DecisionDx-SCC is now commercially available. DecisionDx-SCC is clinically validated as a significant predictor of metastasis and the strongest predictor of risk compared to traditional clinical and ...
Technologybased inWayne, PENNSYLVANIA (USA)
Palvella Therapeutics was founded to serve individuals suffering from rare diseases by developing safe and efficacious therapies that will dramatically enhance their quality of life. We focus on developing therapies that specifically target the root ...
QTORIN™ rapamycin 3.9%is a novel targeted topical therapy being studied for Gorlin syndrome. Palvella is enrolling a phase 2b clinical study (CODY) for people with Gorlin ...
Technologybased inSouth San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
Technologybased inWoburn, MASSACHUSETTS (USA)
Aegle Therapeutics is a first in class, phase 1/2a stage biotechnology company isolating extracellular vesicles including exosomes (EVs) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa ...
Epidermolysis bullosa (“EB”) is a group of rare genetic disorders that manifests as blistering or erosion of the skin in response to little or no apparent trauma. There are many genetic and symptomatic variations of EB. EB is always ...
Technologybased inBoca Raton, FLORIDA (USA)
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for both oncological and non-oncological conditions. The recently introduced Sculptura robotic ...
Built with all the same great features and remarkable efficacy that distinguish the original SRT-100™, the SRT-100 Vision™ delivers the precise, painless calibrated dose of Superficial Radiation Therapy patients and physicians expect, ...
Technologybased inNew York, NEW YORK (USA)
Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build ...
XPO1 has been shown to regulate nuclear export of many of the major tumor suppressor proteins and oncogenic cell growth regulators. Overexpression of XPO1 has been reported in many cancer types and is associated with aggressive tumor behavior and ...
Technologybased inParis, FRANCE
Abivax develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and ...
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer ...
Technologybased inEttlingen, GERMANY
We are a pioneering medical device company focused on transforming the lives of patients with difficult to treat cancers by applying our discoveries in bioelectromagnetics to targeted treatment of cancer. Our patient-based research using low and ...
The TheraBionic P1 produces low levels radiofrequency (RF) electromagnetic fields, which are amplitude-modulated at tumor-specific frequencies. The device is coupled with a spoon-shaped antenna, which is placed in the patient’s mouth, more ...